cyrilzakka/clinical-trials huggingface dataset:
Role of Acetazolamide and Hydrochlorothiazide Followed by Furosemide in Treating Nephrotic Edema

The purpose of this study is to determine whether using furosemide following acetazolamide is effective in treating refractory edema associated with nephrotic syndrome.

Edema is referred to increase in interstitial fluid that is clinically evident. The main causes of generalized edema are heart failure, renal failure, nephrotic syndrome, glomerulonephritis and chronic liver failure. In some cases, edema is treated by management of the underlying disease. However, in some other cases edema may persist and become more severe that needs adjuvant treatments. Because use of diuretics such as furosemide and hydrochlorothiazide is not completely effective in treating severe refractory edema, use of some other diuretics is also recommended. In this double-blind clinical trial, weight and some lab data including blood urea nitrogen, serum creatinine, serum sodium, serum potassium, serum albumin, urine sodium, urine potassium, 24-hour urine volume, 24-hour urine protein and 24-hour urine creatinine of 20 random adult patients with nephrotic syndrome who have refractory edema and GFR\>60 ml/min/1.73m2 and are referred to nephrology clinic of Shiraz University of Medical Sciences will be measured; the patients should not have hypokalemia and other causes of edema such as heart failure or cirrhosis. Then the patients are divided into 2 groups with 10 members in each. The first group will be prescribed 40 mg of furosemide and 50 mg of hydrochlorothiazide and the second one will receive 250 mg of acetazolamide and 50 mg of hydrochlorothiazide daily for 1 week. Then, weight and mentioned lab data will be measured again. After that, all the patients will have 40 mg of furosemide daily for 2 weeks. Then, weight and mentioned lab data will be measured for one more time.

Eligibility Criteria:
Inclusion Criteria:

1. Having refractory edema due to nephrotic syndrome
2. Having GFR\>60 ml/min/1.73m2
3. Being able to come for weekly visit
4. Having the minimum age of 18 years
5. Signing the informed consent form

Exclusion Criteria:

1. Hypokalemia
2. Pregnancy
3. Renal transplant
4. active malignancy or infection
5. acidosis
6. Using NSAIDs
7. Having another causes of edema including liver cirrhosis, heart failure
8. Neurologic or psychiatric problem hindering adherence to the study protocol
Role of the Cystic Fluid Interleukins and Tumor Necrosis Factor (TNF) Levels in Characterizing Pancreatic Cysts Detected by Endoscopic Ultrasound (EUS)

This study aims to find a correlation between cytokines levels and malignancy potential of different cystic types.


Eligibility Criteria:
Inclusion Criteria:

* Patients with pancreatic cyst

Exclusion Criteria:

* None
Trial to Show Non-inferiority / Superiority of an Endoscopic Transforaminal Discectomy to Standard Microdiscectomy

This study compares an endoscopic transforaminal surgical technique for the treatment of a herniated disc to the standard microsurgical procedure. Clinical parameters as well as health economy will be assessed.

The study hypothesis is that the endoscopic approach is equivalent or superior to microdiscectomy.


Eligibility Criteria:
Inclusion Criteria:

* symptomatic lumbar disc herniation
* clinical and radiological evidence of nerve root compression
* failure of conservative treatment for at least 6 weeks

Exclusion Criteria:

* previous lumbar spine surgery
* severe or progressive motor deficit
* BMI \> 40
* cauda equina syndrome
CRP /albumin Ratio and Neutrophil Lymphocyte Ratio in Predicting Activity in IBD Patients

This study aimed to assess the clinical utility of the NLR (neutrophil lymphocyte ratio) and CRP Albumin ratio in predicting activity of IBD Patients in assiut university

IBD definition term for two conditions (Crohn\&#39;s disease and ulcerative colitis) is a chronic idiopathic inflammatory disease affecting the large intestine. It is characterized by relapsing mucosal inflammation. The aim of treatment is to induce and maintain disease remission. Assessing disease activity may help in optimizing the management of IBD patients.

The neutrophil-to-lymphocyte ratio (NLR) is a simple index that can be calculated from the results of ordinary blood tests; it is calculated from a blood sample by dividing the absolute neutrophil count by the absolute lymphocyte count . As the NLR can reflect the systemic status of inflammation or immune response.

The underlying mechanism that the NLR was a predictor of clinilcal relapse in UC patients with Mucosal healing remains poorly understood. Neutrophils induce cytotoxicity and inflammation in UC. A high NLR value may be due to high activity in UC and lowered mucosal barrier function, which may lead to the migration of neutrophils through the gut microbiota .

CRP is routinely used as a surrogate measure of intestinal inflammation and as a prognostic measure of nonresponse to medical therapy and colectomy in patients with IBD.

Eligibility Criteria:
Inclusion Criteria:

Patients more than 18 years newly diagnosed as IBD

-

Exclusion Criteria:

* Patients Not DM Not cardiac failure Not Liver failure No malignancy
A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes

This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar), both with insulin aspart (IAsp) as mealtime insulin in subjects with type 1 diabetes.


Eligibility Criteria:
Inclusion Criteria: - Subjects fulfilling at least one of the below criteria: a) Experienced at least one severe hypo episode within the last year (according to the ADA (American Diabetes Association) definition, April 2013) b) Moderate chronic renal failure, defined as glomerular filtration rate 30 - 59 mL/min/1.73 m\^2 per CKD-Epi (chronic kidney disease epidemiology collaboration) c) Hypoglycaemic symptom unawareness d) Diabetes mellitus duration for more than 15 years e) Recent episode of hypoglycaemia (defined by symptoms of hypoglycaemia and/or episode with low glucose measurement (below or equal to 70 mg/dL \[below or equal to 3.9 mmol/L\])) within the last 12 weeks prior to Visit 1 (screening) - Male or female, age at least 18 years at the time of signing informed consent - Type 1 diabetes mellitus (diagnosed clinically) for at least 52 weeks prior to Visit 1 - Current treatment with a basal-bolus regimen consisting of neutral protamine Hagedorn (NPH) insulin OD (once daily) / BID (twice daily) or insulin detemir (IDet) OD / BID plus 2-4 daily injections of any rapid acting meal time insulin or CSII (with rapid acting insulin) for at least 26 weeks prior to Visit 1 - HbA1c (glycosylated haemoglobin) below or equal to 10% by central laboratory analysis - BMI (body mass index) below or equal to 45 kg/m\^2 Exclusion Criteria: - Treatment with IGlar or IDeg within the last 26 weeks prior to Visit 1 (short term use \[less than or equal to 2 weeks\] is allowed, but not within 4 weeks prior to screening) - Use of any other anti-diabetic agent than those stated in the inclusion criteria within the last 26 weeks prior to Visit 1
Factors Associated With The Risk of Post Tonsillectomy Hemorrhage

factors associated with increase risk of post tonsillectomy hemorrhage and score of associated factors

investigators review the medical records of patients who underwent tonsillectomy with or without adenoidectomy in our facility. None of the included patients had any known coagulopathy. The surgery was performed by several different surgeons, either otolaryngology residents or specialists, and using either cold or bipolar dissection. The procedures were performed under general anesthesia with orotracheal intubation. Bipolar electrocoagulation was used for hemostasis, as well as in some cases vicryl sutures. All medical records were reviewed according to age, gender, indications for tonsillectomy (tonsil hypertrophy causing upper airway obstruction, snoring or sleep apnea, chronic tonsillitis, peritonsillar abscess or suspected malignancy of the tonsils), coagulation profile \[international normalized ratio (INR) and activated partial thromboplastin time values (aPTT)\], type of surgery (tonsillectomy alone or adenotonsillectomy), surgical technique (cold or bipolar dissection), hemostasis method (bipolar electrocoagulation alone or electrocoagulation and sutures) and post-operative hemorrhage and its characterization. In this report, investigators will evaluate patients and collection of data to make a new scoring system that assesses patients according to several preoperative and postoperative factors to know the possibility of patients developing Post tonsillectomy hemorrhage. Post tonsillectomy hemorrhage is divided into two groups according to its severity: minimal hemorrhage that stopped spontaneously/after noninvasive treatment, and hemorrhage requiring reoperation for hemostasis revision in the operating room under general anesthesia.

Postoperative hemorrhage was defined as any bleeding requiring in hospital observation or treatment (medical, compression, cauterization under general anesthesia). Patients who did not seek medical attention (e.g., patients with blood-tinged sputum or only minor bleeding) were not included in the group with post-operative hemorrhage

Eligibility Criteria:
* Inclusion criteria : All cases complicated by post-tonsillectomy bleeding

  1. after elective or emergency tonsillectomy
  2. Primary Hge or secondary Hge
  3. regardless of age, the indication of surgery, surgical techniques
* Exclusion criteria:

  1. patient who have preoperative inherited bleeding disorder
  2. Patients who did not seek medical attention (e.g., patients with blood-tinged sputum or only minor bleeding) riteria:
Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

Phase 3 study to examine the relation between antihypertensive effect and baseline factors exploratively, compared to olmesartan medoxomil in patients with essential hypertension.


Eligibility Criteria:
Inclusion Criteria:

* Male and female subjects aged 20 years or older at informed consent
* Subjects with essential hypertension during run-in period (mean 24 hour systolic blood pressure SBP ≥ 130 and diastolic blood pressure DBP ≥ 80 mmHg and Sitting systolic blood pressure (SBP) ≥ 140 mmHg and \< 180 mmHg, Sitting diastolic blood pressure (DBP) ≥ 90 mmHg and \< 110 mmHg)

Exclusion Criteria:

* Secondary hypertension or malignant hypertension
* Diabetes mellitus with albuminuria
* Serum potassium level \< 3.5 or ≥ 5.1 milliequivalent (mEq)/L
* Reversed day-night life cycle including overnight workers
* estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m\^2.
A University-Community Partnership to Reduce Exposure to Disinfection Byproducts In Appalachia

Appalachian Kentuckians in Martin and Letcher Counties are grappling with a health-threatening drinking water crisis arising from exposures to disinfection by-products (DBPs). DBPs include trihalomethanes (THMs), haloacetic acids (HAAs), chlorate, and other compounds that have been associated with a variety of adverse health effects, including increased risk of bladder cancer and cardiovascular birth defects. This study implements a multi-stakeholder, multi-method approach to improve understanding of, characterize spatial and temporal variations in, and reduce exposure to DBPs in these Appalachian Kentucky counties.


Eligibility Criteria:
Inclusion Criteria:

* Located in Martin or Letcher County water districts
* At least 18 years old
* Able to read/speak in English

Exclusion Criteria:

* Located outside of Martin or Letcher County water districts
Treatment of Anxiety/Depression and Pain Through Relaxation Yoga for Patient With Cystic Fibrosis (CF)

The investigators research question is whether or not yoga effectively alleviates symptoms of pain, sleep disturbance, anxiety and depression in children with cystic fibrosis. If yoga does prove to be effective, the investigators will educate our CF population about the benefits they may experience if they choose to incorporate yoga into their CF therapy. The investigators will also go on to do further research of other complementary alternative medicine therapies.

This is a pre/post-test study with 20 subjects. The subjects will serve as their own controls. Each subject will participate in six yoga sessions over a ten week period. Subjects' symptoms will be evaluated with the use of questionnaires. The investigators will also test cortisol levels on weeks -2, -1, 1, 6, 7, 8. Cortisol is a hormone that is affected by stress. Testing of cortisol throughout the study will help us determine the subjects' stress level throughout the study.

H1: The implementation of a yoga therapy program decreases symptoms of pain within our CF population.

H2: The implementation of a yoga therapy program decreases symptoms of sleep disturbance within our CF population.

H3: The implementation of a yoga therapy program decreases symptoms of anxiety within our CF population.

H4: The implementation of a yoga therapy program decreases symptoms of depression within our CF population.

Eligibility Criteria:
Inclusion Criteria:

* Positive diagnosis of CF
* Males or females within the ages of 9 and 18

Exclusion Criteria:

* No positive diagnosis of CF
* Younger than 9 years of age or older than 18 years of age
* Concomitant illness or disease that may inhibit the patient's ability to participate in the study as determined by the principal investigator
* The patient has participated in an investigational treatment study 30 days prior to pre-session week -2.
* The patient is currently participating in yoga sessions one or more times per week.
INternet-based Programmes FOR the Prevention of Suicidal Ideation in MEDical Students

Two programmes have been built to prevent suicidal ideation; one focuses on stress management based on cognitive and behavioural principles and the other on health promotion.

The main objective will be assessing their respective effectiveness on suicidal ideation (at least one occurrence over a 12-month period after the end of the intervention), through a randomized controlled trial, in medical students and interns.

Eligibility Criteria:
Inclusion Criteria:

* Being registered in the fourth year of medical studies or in the first year of residency (internship), as they appear as two critical periods over medical studies
* Being registered in the i-Share cohort
* 18 year-old and over
* Speaking and reading French
* Having given an informed consent
* Ability to understand the type, the aims and the methodology of the study
* Agreement for online clinical assessment
* Having a mobile phone number and an e-mail address
* To be beneficiary of a health insurance programme

Exclusion Criteria:

* Refusing to participate
* Protective supervision: curatorship, guardianship
Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine

A study to review Wilson disease patients who have previously been prescribed d- Penicillamine but were changed to trientine as treatment for their disease, and to follow them for a further 12 months.

A retrospective study to review Wilson disease patients who have previously been prescribed d- Penicillamine but were changed to trientine as treatment for their disease, and to follow them prospectively for a further 12 months.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged 1 year to 90 years of age.
* Physician established diagnosis of Wilson disease based on a Ferenci score \> 3.
* Documented treatment with d-Penicillamine, withdrawal of treatment with d- Penicillamine, followed by treatment with trientine for at least 6 months at date of informed consent.
* Able/willing to provide written informed consent.
* For enrolment in the prospective part, enrolment in the retrospective part of the study is required.

Exclusion Criteria:

* Incomplete history of medication use for trientine from initial diagnosis to latest follow up.
* Unavailable outcome data for hepatic and neurological course of disease at assessment time points.
* Patients with acute liver failure and fulminant hepatic disease with fatal outcome.
* Hypersensitivity to trientine and severe anaemia.
Safety and Efficacy of Multisensory Stimulation Virtual Reality for Stroke Patients.

This was a single-blind randomized controlled trial of multisensory stimulation virtual reality to improve motor and cognitive dysfunction in stroke patients.

This was single-blind randomized controlled intervention study. Each stroke subject underwent screening period, baseline assessment period, intervention period, endpoint assessment period.

The screening period include the verification of inclusion/exclusion criteria and the acquisition of informed consent.

Baseline and endpoint assessment period include motor function related scales were evaluated (muscle strength, muscle tone, Fugl-Meyer scale, Berg balance scale); cognitive function related scale assessment \[Brief Mental State Examination Scale (MMSE), Montreal Cognitive Assessment (MoCA), drawing clock test, Shape connection test A.B, standardized digital modal experiment, auditory word Learning Test\], emotional correlation scale assessment (Hamilton Depression Scale, Hamilton Anxiety Scale), and activity of daily living scale ADL scale. Meanwhile, quantitative evaluation of motor function three-dimensional gait detection and assessment of brain functional activation (fNIRs tests and fMRI) were synchronously completed.

The intervention period included multi-sensory stimulation immersive VR+ treadmill training with suitable for training intensity in the experimental group and only treadmill training similarly with suitable for training intensity in the control group. 20 minutes a day for 30 days, a total of 600 minutes (training frequency is adjusted according to the patient's own conditions).

Preliminary validation of effectiveness assessment includes Fugl-Meyer scale, Berg balance scale, and three-dimensional gait detection. Preliminary validation of the safety assessment includes fall and dizzy incidents.

Eligibility Criteria:
Inclusion Criteria:

1. Diagnosis of stroke by neuroimaging (CT or MRI) assessment
2. 18-85 years old
3. Be able to walk with minor assistance
4. Can tolerate the rehabilitation training of this experiment
5. First stroke
6. Be able to follow instructions to complete the test
7. Patients who signed informed consent

Exclusion Criteria:

1. The test could not be tolerated due to organic disease
2. There is a serious mental illness resulting in inability to cooperate with or tolerate this test
3. is participating in another clinical trial involving an investigational drug or physical therapy
4. Patients who have not signed informed consent
Flagyl Microbiome in Crohn's Disease

This study will compare the types of bacteria in the colon before and after colon resection surgery. The investigator will also compare standard post-operative antibiotic treatment to flagyl (metronidazole) treatment post-operatively to see if giving the antibiotic, decreases the incidence of return of Crohn's disease.

Participants who are scheduled for colon resection for Crohn's disease will be invited to take part in this randomized study. Participants will be randomized 1:1 to either Metronidazole 250 mg three times a day, starting after surgery, for three months, or the local usual standard of care after surgery, which may be a different antibiotic prescribed by the physician.

Participants will also provide a stool sample at the following time points: prior to surgery, the day of discharge, at their follow-up appointment (usually about two weeks after surgery), three months, and six months.

Participants will also be followed to determine their clinical outcome.

Eligibility Criteria:
Inclusion Criteria:

* 20-80 years old who is deemed an acceptable surgical candidate for ileocolic resection.

Exclusion Criteria:

* any patients that are dependent on total parenteral nutrition and unable to tolerate oral intake
* patients who will undergo resection but will have an ileostomy created
* patients on maintenance antibiotics for their disease
Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

This is a parallel, two-arm, open-label, multicenter phase IA/IB study of LBH589 (oral formulation) alone and in combination with docetaxel in patients with progressing hormone refractory prostate cancer. This study is designed to determine the maximum tolerated dose of LBH589 as a single agent and in combination with docetaxel and prednisone 5 mg two times a day , and to characterize the safety, tolerability, biologic activity and pharmacokinetic profile


Eligibility Criteria:
Inclusion criteria:

* Histologically documented adenocarcinoma of the prostate.
* Patients must have metastatic disease with at least one measurable soft tissue lesion that can be assessed by computerized tomography (CT), or magnetic resonance imaging (MRI) and/or detectable lesion(s) on bone scintigraphy scan. Patients with only elevated prostate specific antegen (PSA) levels are not eligible for entry.
* Patients who have undergone medical castration must continue Luteinizing hormone-releasing hormone (LHRH) agonist or antagonist therapy during study treatment
* Patients must be able to provide written informed consent

Exclusion criteria:

* Patients with prior or concurrent brain metastases
* Impaired cardiac, gastrointestinal, kidney, or liver function
* Use of therapeutic androgens

Other protocol-defined inclusion/exclusion criteria may apply
Percutaneous Electrical Nerve Stimulation Compared to Passive Assisted Neurodynamics in Brachial Plexus Neuropathy

Brachial plexus neuropathies, specifically of the median, radial, ulnar, suprascapular, axillary and dorsal scapular nerves, can arise when a peripheral nerve trunk or nerve root is subjected to injury, compression, inflammation or ischemia, resulting in reduced physical capabilities of the peripheral nervous system. Although pharmacological treatments provide mild symptomatic relief in the short term, they are not without side effects.

Neurostimulation techniques may be an effective treatment option for peripheral brachial plexus neuropathies. Some of these procedures are transcutaneous electrical nerve stimulation (TENS) or percutaneous electrical nerve stimulation (PENS). Although some case series have documented a positive effect in relation to ultrasound-guided PENS for subjects with subacromial pain syndrome or postsurgical pain, the lack of studies, to our knowledge, analyzing the effects of percutaneous electrical nerve stimulation, in relation to pain and paresthesias in subjects with brachial plexus neuropathy, warrants investigation for this goal.


Eligibility Criteria:
Inclusion Criteria:

* Subjects with upper limb neural symptomatology between 18 and 60 years of age, presenting two or more of the following conditions:
* Paresthesias in any territory of the shoulder girdle, arm or hand
* Pain at rest in any territory of the upper extremity.
* Pain at rest in any upper extremity territory
* Sensations of electric shock in any territory of the shoulder girdle, arm or hand.
* Allodynia or cutaneous hyperalgesia in any territory of the shoulder girdle, arm or hand.

Exclusion Criteria:

* Less than 2 weeks of evolution
* Fracture in the affected upper extremity
* Suffering from another joint disorder such as osteoarthritis or rheumatic disease
* Suffering from generalized neuropathies due to neuromuscular disease or medication
* Inability to understand instructions or sign informed consent.
* Wearing a pacemaker or any electrical device implanted in the body
* Epilepsy
* Aversion or fear of needles
* Pregnant.